Strong performance in US market to support growth of Indian pharma industry in FY24- ICRA

Strong performance in US market to support growth of Indian pharma industry in FY24: ICRA

ICRA announced that it expects the revenues of a sample set of 25 Indian pharmaceutical companies (which account for ~60% of the overall revenues of the Indian pharmaceutical industry) to expand by 9-11 percent in FY2024, post a YoY growth of 10% in FY2023.

According to the credit rating agency, the OPM for the sample set is projected to improve to 22-23 pecent in FY2024, against 20.7 percent in FY2023, supported by new product launches backed by increased focus on complex generics/specialty molecules, easing of pricing pressure, and some benefits of volume expansion and better pricing due to product shortages in the US market.

“The projected revenue growth in FY2024 will be primarily supported by 11-13% expansion in the US market and 7-9% growth in the domestic market, while revenues from the European market and emerging markets are expected to rise by 11-13% and 13-15%, respectively. The US has always been a key market for most leading Indian pharmaceutical companies, accounting for a sizeable share of their revenues. However, the share of revenues from the US market for ICRA’s sample set of companies declined to ~35% in FY2022 vis-à-vis 40% in FY2020 owing to consistent pricing pressure, lack of major blockbuster products going off-patent and increased regulatory scrutiny in the recent years,” the agency said in a statement.

Nonetheless, with easing of pricing pressure, significant new launches and shortages of some products, the same increased to 37% in FY2023 and 38% in H1 FY2024.

“Apart from some key drugs going off-patent, product shortages in select therapeutic segments (oncology, pain/anesthesia, cardiovascular among others) in the recent quarters have also been a growth driver for generic companies in the US market to some extent. These shortages in the US market have been partly caused by lower production/ discontinuation of operations by some pharmaceutical companies (including local ones) owing to persistent pricing pressure, supply chain challenges and increased regulatory scrutiny by the United States Food and Drug Administration (USFDA). The incidences of warning letters and import alerts issued to manufacturing facilities of the Indian pharmaceutical companies have increased over the past year and remain a key credit risk. These have led to delays in product launches for some companies, translating into failure to supply penalties and entailing significant cost burden towards remedial measures including hiring consultants and consuming additional management bandwidth, in turn impacting the profit margins,” Deepak Jotwani, Assistant Vice President & Sector Head, ICRA, said.

ICRA expects the revenue growth of its sample set of companies in the domestic market to be 7-9% in FY2024, supported by price increases and new product launches. In H1 FY2024, ICRA’s sample set of companies witnessed a 7.2% YoY growth, negatively impacted by the price reductions required to be undertaken because of price caps by the National List of Essential Medicines (NLEM) on various products besides an uneven monsoon, which affected acute therapy sales.

The revenue growth of the sample set of companies in the European market has picked up considerably in the current fiscal, largely on the back of a low base, uptick in the base business (both branded and generics segment), new product launches (especially injectables) and incremental revenues from new tender wins (in countries such as Germany) in addition to 8.8% depreciation of the INR against the EUR in 9M FY2024.

ICRA foresees the research and development expenses for its sample set of companies to stabilise at 6.5-7% of their revenues as the companies will optimise their spending, focusing more on complex molecules and specialty products against plain vanilla generics.

Leading Indian pharmaceutical companies have made sizeable strategic acquisitions in the recent past to enhance market share in select geographies/therapeutic areas. Most of these acquisitions have been towards strengthening therapeutic coverage, primarily in the US and Indian markets.

This is expected to provide diversification benefits and support revenue growth for these companies, going forward. The sizeable quantum of most deals also indicates the elevated risk appetite of these pharma majors. Given the sizeable debt-funded acquisitions by some companies in FY2023, the Total Debt/OPBDITA of the sample set of companies increased to 1.25x as on March 31, 2023 (0.9x as on March 31, 2022).

Nevertheless, this metric is expected to remain comfortable at 1.0-1.1x over the near-to-medium term, despite high capital expenditure (towards capacity expansion, maintenance and upgradation), supported by healthy internal accrual generation.